Filter
Therapeutic AreaRegionDeal TypeNon Pharma
Anwenden
array(1) { [0]=> object(WP_Term)#4389 (16) { ["term_id"]=> int(68) ["name"]=> string(12) "Transactions" ["slug"]=> string(15) "transactions-de" ["term_group"]=> int(0) ["term_taxonomy_id"]=> int(68) ["taxonomy"]=> string(8) "category" ["description"]=> string(385) "To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle. Please find below selected transactions completed by WINDOME BANKING PARTNERS' employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023)." ["parent"]=> int(0) ["count"]=> int(73) ["filter"]=> string(3) "raw" ["cat_ID"]=> int(68) ["category_count"]=> int(73) ["category_description"]=> string(385) "To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle. Please find below selected transactions completed by WINDOME BANKING PARTNERS' employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023)." ["cat_name"]=> string(12) "Transactions" ["category_nicename"]=> string(15) "transactions-de" ["category_parent"]=> int(0) } }
Februar 2023

Conseil non-exclusif de Bridgepoint dans l’acquisition d’une participation majoritaire dans Laboratoire Vivacy SA.

Undisclosed terms.
Dezember 2021

Outlicensing of the global rights to the Italian range of Dermocosmetics to DermaForce (the Skinbetter Science Division) for an undisclosed double-digit upfront payment, royalties and milestones.

Undisclosed terms.
Oktober 2020

Divestiture to AbbVie-Allergan Aesthetics for an undisclosed purchase price. Transferred brands include Crystalys, HArmonyCa, Hydryalix and Hydryal, Composite Matrix Dermal Fillers based on CAHA.

Undisclosed terms.
Mai 2020

Advisor in the completion of a € 10m share capital increase and realization of a Fairness Opinion for Market Valuation.

€ 10m Upfront payment.
März 2020

Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.

€ 5m Upfront payment.
September 2019

Exclusive Financial Advisor to BMG Pharma to enter a Distribution, Supply and Licensing Agreement covering a range of Oral-Care brands with Pierre Fabre Médicament.

Undisclosed terms.
März 2019

Share Capital Increase via preferred Convertible Offering to a consortium of new investors to support international deployment.

CHF 30m Share capital increase.
Januar 2019

Exclusive Financial Advisor to Croma in the structuring of the strategic partnership for the manufacturing and supply of Menarini-Relife’s lead dermal filler Range Definisse.

Undisclosed terms.
Dezember 2018

Exclusive Financial Advisor to Croma in constructing a 70-30% US- based exit JV to be majority- led by Korean Toxin specialist Hugel Corporation and concurrent Divestiture of its Canadian and Australian Subsidiaries to Hugel.

US$ 90m Upfront payment.
Oktober 2018

Exclusive Financial Advisor to the Largest Polish Medical Aesthetic Group for the Divestiture of a 51% stake to Abris Capital, a Polish Growth Capital PE Fund and concurrent Entry into a Shareholders’ Agreement.

Undisclosed terms.
Juni 2018

Exclusive Financial Advisor to Bloomage for the completion of a strategic partnership including the investment in a minority equity ownership and entry into a long- term licensing agreement.

Undisclosed terms.
Juni 2017

Supply Agreement for two BMG original oral and dental hygiene products: Aftacure Gel and Aftacure Spray.

Undisclosed terms.